CDKN2A and acute lymphoblastic leukemia: Iacobucci et al. [24] have shown that the presence of IKZF1 deletion combined with deletion of the ARF locus encoded by the CDKN2A was associated with poorer prognosis and higher risk of relapse and can lead to resistance to TKIs targeted therapy in adults with BCR-ABL1 positive B-ALL.